Rodman & Renshaw analyst Tony Buter downgraded Atara Biotherapeutics (ATRA) to Neutral from Buy with a price target of $7, down from $25, after the FDA placed a clinical hold on the company’s active investigational new drug applications
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics reports clinical hold placed on Ebvallo programs, ATA3219
- Atara Biotherapeutics price target lowered to $17 from $21 at Canaccord
- Atara Biotherapeutics trading resumes
- Atara Biotherapeutics remains eligible for $60M milestone payment
- Atara announces Ebvallo CRL did not find clinical efficacy deficiencies